Kathryn Mazina

Statistics

Publications

Citations

1.3K

H-Index

Active since

1984

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Institute for Medical Research

Bristol-Myers Squibb (Sweden)

Kathryn Mazina is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacology, medicine, and pharmacokinetics of anticancer drugs.

Publications per year

1984–2014

Publications

First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors

Debashis Sarker, Joo Ern Ang, Richard D. Baird et al. · Clinical Cancer Research · 2014 · 360 citations · Full text

Medicine, Oncology, Pharmacology +15

Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I.

Robert B. Lobell, Dongming Liu, Carolyn A. Buser et al. · PubMed · 2002 · 121 citations

Medicine, Pharmacology, Pharmacotherapy +14

A Study to Determine the Effects of Food and Multiple Dosing on the Pharmacokinetics of Vorinostat Given Orally to Patients with Advanced Cancer

Eric H. Rubin, Nancy Agrawal, Evan Friedman et al. · Clinical Cancer Research · 2006 · 113 citations · Full text

Pharmacy, Oncology, Pharmacology +17

A phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies.

Carolyn D. Britten, Eric K. Rowinsky, Steven L. Soignet et al. · PubMed · 2001 · 88 citations

Pharmacy, Pharmacokinetics, Pharmacology +9

A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QD in patients with advanced solid tumors.

Amy J. Wagner, Johanna C. Bendell, Saoirse Dolly et al. · Journal of Clinical Oncology · 2011 · 72 citations

Medicine, Pharmacokinetics, Pharmacology +16

1–5 of 19